A federal appeals court recently heard arguments in a case, which a group of Texas hospitals filed challenging a Department [...] …
Articles by : Shannon Young, Associate Editor/Senior Writer
Four major drugmakers recently announced refunds to 340B covered entities that purchased certain medications between 2022 and 2024, following recalculations [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Breaking News
Carter, Harshbarger Reintroduce Controversial 340B ACCESS Act in U.S. House—This Time Without a Key Supporter
Two key U.S. House Republicans and vocal 340B program critics on Wednesday reintroduced controversial 340B overhaul legislation—but unlike last year’s [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
340B covered entities in the prime vendor program (PVP) spent nearly $44 billion on 340B drugs in 2021—up from $6.6 [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A national hospital trade group urged federal officials Monday to investigate whether five major drugmakers engaged in anticompetitive practices while [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A South Carolina Republican U.S. House lawmaker recently honored the life and legacy of Sue Veer, a nationally recognized leader [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Washington D.C.’s most powerful drug industry trade group this week ramped up its attacks on the 340B program, launching what’s [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A New Jersey-based pharmaceutical manufacturer recently became the 39th drugmaker to enact 340B contract pharmacy restrictions. Mitsubishi Tanabe Pharma America [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The 340B program continued to garner strong lobbying attention on Capitol Hill this spring, despite Congress’ focus on a GOP-backed [...] …